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Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mutations in the dystrophin-encoding DMD gene.
The DMD gene, spanning over 2.4 megabases along the short arm of the X chromosome (Xp21.2), is the largest genetic
locus known in the human genome. The size of DMD, combined with the complexity of the DMD phenotype and the
extent of the affected tissues, begs for the development of novel, ideally complementary, therapeutic approaches.
Genome editing based on the delivery of sequence-specific programmable nucleases into dystrophin-defective cells has
recently enriched the portfolio of potential therapies under investigation. Experiments involving different programmable
nuclease platforms and target cell types have established that the application of genome-editing principles to the
targeted manipulation of defective DMD loci can result in the rescue of dystrophin protein synthesis in gene-edited cells.
Looking towards translation into the clinic, these proof-of-principle experiments have been swiftly followed by the
conversion of well-established viral vector systems into delivery agents for DMD editing. These gene-editing tools consist
of zinc-finger nucleases (ZFNs), engineered homing endonucleases (HEs), transcription activator-like effector nucleases
(TALENs), and RNA-guided nucleases (RGNs) based on clustered, regularly interspaced, short palindromic repeats (CRISPR)
–Cas9 systems. Here, we succinctly review these fast-paced developments and technologies, highlighting their relative
merits and potential bottlenecks, when used as part of in vivo and ex vivo gene-editing strategies.Background
Duchenne muscular dystrophy (DMD) is a lethal X-
linked genetic disorder (affecting approximately 1 in
5000 boys) [1] caused by mutations in the ~2.4-mega-
base DMD gene [2] which lead to irrevocable muscle
wasting owing to the absence of dystrophin in the
striated muscle cell lineage [3]. Although dystrophin-
disrupting mutations can be of different types, 68 % of
them consist of large intragenic deletions [4]. These
deletions can be found along the entire length of the
enormous DMD locus, with 66 % of them nested within
a major, recombination-prone, hotspot region spanning
exons 45 through 55 [4]. The resulting joining of exons
flanking DMD-causing mutations by pre-mRNA splicing
yields transcripts harboring out-of-frame sequences and
premature stop codons, which are presumably degraded
by nonsense-mediated mRNA decay mechanisms.
In muscle cells, the long rod-shaped dystrophin
protein anchors the intracellular cytoskeleton to the* Correspondence: M.Goncalves@lumc.nl
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bedded in the plasma membrane called the dystrophin-
associated glycoprotein complex (DGC). This structural
link is fundamental for proper cellular signaling and struc-
tural integrity. Indeed, in the absence of dystrophin, a re-
lentless degenerative process is initiated that consists of
the substitution of muscle mass by dysfunctional fibrotic
and fat tissues [3]. As time elapses, patients with DMD be-
come dependent on a wheelchair for ambulation and, later
on, require breathing assistance. Crucially, with the aid of
palliative treatments, which include supportive respiratory
and cardiac care, the life expectancy of patients with
DMD is improving and a greater proportion of these
patients now reach their late 30s [3, 5].
Targeting the root cause of DMD
The complexity of DMD, combined with the extent of
affected tissue, demands the development of different,
ideally complementary, therapeutic approaches. The goal
of pursuing parallel approaches is to target different
aspects and stages of the disease and hence maximize
the length and quality of patients’ lives. Towards this
end, various candidate therapies are currently undere is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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include: (1) mutation-specific exon skipping via modula-
tion of pre-mRNA splicing by antisense oligonucleotides;
(2) compensatory upregulation of dystrophin’s autosomal
paralog utrophin by small-molecule drugs or artificial
transcription factors; (3) cell therapies involving allogenic
myogenic stem/progenitor cell transplantation; and (4) gene
therapies based on the delivery of shortened versions of dys-
trophin (for example, microdystrophins) to affected tissues.
Of note, these recombinant microdystrophins are devoid of
centrally located motifs, consisting mostly of spectrin-like
repeats, that are, to some extent, dispensable. The
miniaturization bypasses the fact that the full-length 11-
kilobase (kb) dystrophin coding sequence is well over the
packaging limit of most viral vector systems.
More recently, genome-editing strategies based on
sequence-specific programmable nucleases have been
proposed as another group of therapies for DMD
[7–10]. Programmable nucleases are tailored to induce
double-stranded DNA breaks (DSBs) at predefinedFig. 1 Milestones on the path towards somatic genetic therapies for Duch
time marks correspond to the first release date of the referenced articles (f
CRISPR–Cas9 clustered regularly interspaced short palindromic repeat-assoc
double-stranded DNA break, HE homing endonuclease, rAAV recombinantpositions within complex genomes [11–13]. In chrono-
logical order of appearance, these enzymes are: zinc-
finger nucleases (ZFNs) [14], engineered homing endo-
nucleases (HEs) [15], transcription activator-like effector
nucleases (TALENs) [16–18], and RNA-guided nucleases
(RGNs) based on dual RNA-programmable clustered,
regularly interspaced, short palindromic repeat (CRISPR)–
Cas9 systems [19–22] (Fig. 1). HEs, also known as mega-
nucleases, from the LAGLIDADG family can be engi-
neered to cleave DNA sequences other than those of their
natural target sites. The designing of new substrate speci-
ficities depends, however, on complex protein engineering
efforts involving the screening of large combinatorial as-
semblies of HE parts [15]. Regardless, redesigned HEs
were shown to create indel footprints at intronic DMD
sequences, albeit at very low frequencies (<1 % of target
alleles in human myoblasts) [23]. In contrast to the con-
struction of redesigned HEs, the modular nature of the
DNA-binding motifs of ZFNs and TALENs makes them
more amenable to protein engineering [14, 16–18]. Ofenne muscular dystrophy that rely on viral-based DMD editing. The
or example, advanced online publication). AdV adenoviral vector,
iated Cas9 nuclease, DMD Duchenne muscular dystrophy, DSB
adeno-associated virus, TALE transcription activator-like effector
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particularly straightforward owing to a simple one-to-one
relationship between the binding of each of their DNA-
binding modules, that is, transcription activator-like
effector (TALE) repeats, and a specific nucleotide [16, 17].
Among other features, ZFNs and TALENs differ from
RGNs in that they are chimeric enzymes that assemble at
their target nucleotide sequences as catalytically active
dimers through protein–DNA binding, whereas RGNs are
ribonucleoprotein complexes whose DNA cutting specific-
ities are ultimately governed by DNA–RNA hybridization.
Indeed, RGNs consist of a Cas9 endonuclease and a
sequence-customizable single-guide RNA (sgRNA) moiety
that leads the protein component to induce a site-specific
DSB. Typically, the target site consists of 18–20 nucleo-
tides complementary to the 5′ end of the sgRNA and a
protospacer adjacent motif (PAM; NGG and NNGRRT in
the case of the prototypic Streptococcus pyogenes Cas9 and
its smaller orthologue Staphylococcus aureus Cas9, re-
spectively) [19, 24]. Hence, in comparison with the strictly
protein-based systems, RGNs are more versatile owing to
their mode of construction, which does not involve pro-
tein engineering [11–13].
Regardless of the DNA cutting system that is selected,
the repair of the ensuing DSBs by different endogenous
cellular DNA repair processes can yield specific genome
editing outcomes. For example, the engagement of hom-
ologous recombination (HR) and non-homologous end
joining (NHEJ) mechanisms can result in targeted
exogenous DNA additions and endogenous DNA dele-
tions, respectively [11–13]. The incorporation of small
insertions and deletions (indels) following the repair of
DSBs by NHEJ can also be exploited for knocking out
trans-acting and cis-acting genomic elements [11–13].
By operating at the DNA level, such interventions can
potentially lead to the correction of disease-causing
mutations on a permanent basis.
DMD gene editing
DMD editing based on targeted addition of “exon
patches” corresponding to missing or disrupted coding
sequences might become ideal therapeutic options as
they result in the synthesis of full-length dystrophin [8,
25]. Proof-of-principle experiments demonstrated that
combining DMD-repairing exon patches with engi-
neered meganucleases [25], RGNs, or TALENs [8] can
indeed restore full-length message coding for dystrophin.
At present, however, most DMD editing approaches
under investigation are based on inducing NHEJ to
disrupt or delete specific sequences [7–10]. These strat-
egies exploit the fact that, in contrast to HR, NHEJ is
active in both dividing and post-mitotic cells [26, 27],
which makes these approaches more amenable to both
ex vivo and in vivo applications (Table 1). The NHEJ-based strategies also capitalize on the fact that internally
truncated in-frame DMD transcripts, despite being
shorter than the full-length DMD transcript, often yield
functional dystrophins [28–30]. Indeed, such dystrophins
are characteristic of patients with Becker muscular dys-
trophy, whose disease phenotypes are milder than those
of their counterparts with DMD [28–30]. Therefore,
programmable nucleases have been tailored for correct-
ing defective DMD alleles by targeting: (1) splicing sites
for inducing DNA-borne exon skipping; (2) exonic se-
quences for resetting reading frames and “overwriting”
downstream premature stop codons; and (3) flanking
intronic sequences for directly excising mutations
through the use of pairs of programmable nucleases
(multiplexing) [7–10]. DNA-borne exon skipping by
NHEJ-mediated splicing motif knockout and reading-
frame resetting by frame shifting are mutation-specific
and rely on the fraction of indel footprints that yield in-
frame sequences. Importantly, the resulting indels might
introduce immunogenic epitopes into de novo-synthesized
dystrophin molecules. Depending on certain variables (for
example, revertant mutation backgrounds), these epitopes
might be recognized as foreign by the immune system. In
part related to this potential issue, T-cell immunity directed
to epitopes corresponding to wild-type dystrophin se-
quences was detected in two patients undergoing a clinical
trial based on recombinant adeno-associated viral vector
(rAAV) delivery of a microdystrophin construct [31].
In contrast to those triggering single-exon deletions,
the DMD correction approaches based on targeted
multi-exon deletions do not give rise to indel-derived
epitopes and are applicable to a wider range of DMD-
causing genotypes, with de novo-generated intronic
junctions leading to predictable in-frame mRNA tem-
plates [10, 32]. However, multiplexing approaches carry
increased risks for unwarranted, possibly deleterious,
genome-modifying events (for example, off-target DSBs,
inversions, and translocations), owing to their depend-
ency on two programmable nucleases rather than one
[12]. These increased risks will be present despite the
fact that targeted DSBs in boys with DMD will be
restricted to a single allele.
Viral-based DMD editing
The clinical application of DMD-editing concepts will re-
quire improved methods for delivering large and complex
molecular tools into target cells, as well as increasing the
efficiency, specificity, and fidelity of the ensuing DNA
modifications [12]. Similarly to their effective contribution
to “classic” gene replacement therapies [33], viral vectors
are expected to become instrumental tools for investigat-
ing and developing therapeutic in vivo and ex vivo gene-
editing approaches (for a recent review on the adaptation
and testing of viral vector systems for genome editing




Ex vivo In vivo
Background × Knowledge about the grafting of different types of myogenic
cells into recipient human muscles is scarce
✓ Builds upon an increasing amount of knowledge about the
in vivo administration of viral vectors into recipient human
muscles (for example, microdystrophin-encoding rAAVs)
Production ✓ Potentially less dependent on large-scale production of viral
vectors
× Reliant on the upscaling of cell culture systems
× The required numbers of certain myogenic cell types might
not be achievable owing to senescence (for example,
myoblasts)
× The current protocols do not permit culturing bona fide
skeletal muscle stem cells (that is, satellite cells) in vitro
✓ Independent from the upscaling of cell culture systems
× More reliant on large-scale production of viral vectors
Delivery ✓ Well-defined genetic modification environment that enables
careful monitoring of procedures, events, and outcomes
✓ Lower stringency for monitoring the biodistribution (for
example, gonads and shedding of vector elements)
× Protocols for effective myogenic cell engraftment, migration,
and differentiation need to be improved (for example, via
signaling gradients and cell-autonomous reprogramming of
iPSCs)
× Local and locoregional administration of myogenic cells
might be difficult to apply to a broad range of muscle groups
× Protocols for the systemic delivery and tissue homing of
myogenic cells need to be developed
✓ Direct exposure to gene-editing tools facilitates in situ correc-
tion of differentiated striated muscle tissues
✓ Possible in situ transduction of resident tissue-specific stem
cells might generate a long-term source of gene-edited
muscle progenitor cells
✓ Expanding range of viral vector pseudotypes enables the
investigation of different transduction patterns—for example,
tropism for affected tissues—while avoiding APCs. Such
transductional targeting can be combined with transcriptional
targeting (that is, use of tissue-specific promoters)
× Local and locoregional administration of viral vector particles
might be difficult to apply to a broad range of muscle groups
× Protocols for the systemic delivery of viral vectors to affected
tissues need to be improved
× Higher stringency for monitoring the biodistribution (for
example, gonads and shedding of vector elements)
Strategy ✓ Relies mostly on targeting replicating cells that are amenable
to gene-editing approaches based on NHEJ as well as HR
× Relies mostly on targeting post-mitotic cells, which are less
amenable to HR-based gene-editing principles
Immunology ✓ Minimizes the exposure of the patient to immunogenic
components of viral vectors and gene-editing tools
✓ Possibly compatible with the re-administration of gene-
edited autologous cells
✓ Avoids the blocking of viral vector particles by neutralizing
antibodies present in the majority of the human population
× Patient exposure to immunogenic components of vector
particles and gene-editing tools. Possible mounting of cellular
responses to transduced cells displaying foreign epitopes
× Anti-vector neutralizing antibodies in the majority of the
human population. Serotype cross-neutralizing activity might
render vector pseudotyping and vector re-administration
ineffective
In vivo approaches entail the direct administration of gene-editing viral vectors to the patient. Ex vivo approaches encompass the in vitro transduction of patient-
derived cells (for example, myogenic stem or progenitor cells) with gene-editing viral vectors, which is followed by cell culture and autologous transplantation back into
the patient. Both treatment modalities can, in principle, be applied either locally or systemically. APCs antigen-presenting cells, HR homologous recombination, iPSCs
induced pluripotent stem cells, NHEJ non-homologous end joining, rAAVs recombinant adeno-associated viruses
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have all been shown to be amenable to viral vector deliv-
ery [35–37] (Fig. 1). More recently, adenoviral vectors
(AdVs) and rAAVs have been successfully converted into
DMD-editing agents in both patient-derived cells and
mouse models of DMD [38–42] (Fig. 1).
In vivo
The Dmdmdx mouse model has a (mild) dystrophic
phenotype that is due to a nonsense mutation located in
exon 23 of the Dmd gene; historically, this has been the
principal animal model for investigating DMD-targeted
therapies and certain pathophysiological aspects of the
disease [43]. In one study, conventional, commonly used,
serotype-5 AdVs constructed to encode either S. pyo-
genes Cas9 or sgRNAs that targeted sequences flanking
Dmd exons 21 through 23 were co-injected into thegastrocnemius muscles of newborn Dmdmdx mice [38].
At 3 weeks post-injection, dystrophin synthesis was
readily detected in transduced muscle fibers. A semi-
quantitative assay based on western blot analysis esti-
mated that these fibers contained ~50 % of the wild-type
levels of dystrophin. The gene-edited muscle regions dis-
played reduced Evans blue dye uptake under rest and
force-generating conditions, indicating improved muscle
fiber integrity.
A notorious characteristic of prototypic serotype-5
AdVs is their immunogenicity and, although they can be
made without viral genes [34, 44], capsid-cell interac-
tions can still trigger strong innate immune responses
[45, 46]. In addition, the high prevalence of neutralizing
antibodies directed against the capsids of serotype-5
AdVs in the human population has contributed to
spurring the development of AdVs based on alternative
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minants have in fact precluded the efficacious deploy-
ment of AdV technologies in “classic” gene therapy
settings in which long-term maintenance of transduced
cells is a prerequisite. AdVs are currently mostly used in
human individuals either as oncolytic or vaccination
agents [47]. The use of AdVs in translational in vivo
gene editing will require dampening their immunogen-
icity and improving their targeting to specific cell types
or organs. These efforts will be heavily guided by in-
sights into the biology of host–vector interactions [45,
46]. For example, while serotype-5 AdVs bind through
their fibers to the coxsackievirus and adenovirus recep-
tor (CAR) to enter cells in vitro [48], their uptake by
liver cells after intravenous administration in vivo is
CAR-independent and governed by the interaction of
their hexons with blood coagulation factors [49].
Three other studies investigated the in vivo delivery of
RGN components (that is, sgRNAs and Cas9 nucleases)
by capsid-pseudotyped rAAVs for creating the in-frame
deletion of Dmd exon 23. These rAAV particles consist of
rAAV DNA from serotype 2 packaged in capsids from
AAV serotype 8 (rAAV-8) [40] or serotype 9 (rAAV-9) [39,
41], whose tropisms for striated mouse muscle had previ-
ously been established [50, 51]. Pairs of these vectors en-
coding sgRNAs and either S. pyogenes Cas9 [39] or the
smaller S. aureus Cas9 [40, 41] were co-administered into
newborn and adult Dmdmdx mice. Nelson and colleagues
detected abundant dystrophin protein synthesis 8 weeks
after co-injecting a mixture of rAAV-8 particles encoding
S. aureus Cas9 and cognate sgRNAs into tibialis anterior
muscles [40]. Importantly, treated muscles had improved
contractibility and force-generating functions. Finally, by
capitalizing on the well-established high transduction ac-
tivity of various tissues by rAAV-8 after systemic adminis-
tration in mice [50], Nelson and colleagues were able to
detect dystrophin in cardiac muscle tissue after a single
intravenous injection [40].
Instead of rAAV-8, Long and colleagues used rAAV-9
to introduce S. pyogenes RGN complexes into striated
muscle tissues of newborn Dmdmdx mice [39]. Dys-
trophin was detected in striated muscle tissues after
local and systemic administration of the engineered viral
vectors [39]. Consistent with the slow kinetics of gene
expression from rAAVs, which might in part be related
to the processes underlying the conversion of vector
DNA from a single-stranded to a transcriptionally active
double-stranded form [52], a time-dependent increase in
dystrophin buildup was observed. For instance, tibialis
anterior muscles of postnatal day 12 Dmdmdx mice sub-
jected to direct intramuscular injections with the engi-
neered viral vector contained approximately 8 and 26 %
of dystrophin-positive fibers at 3 and 6 weeks post-
administration, respectively [39].In the third study, Tabebordbar and coworkers used
rAAV-9 pairs for delivering S. aureus Cas9 and sgRNAs
to the tibialis anterior muscle of dystrophin-defective
Dmdmdx mice [41]. Similarly to the results of the two
other studies obtained after rAAV-mediated Dmd exon
23 deletion experiments [39, 40], administration of the
rAAV-9 pairs led to robust rescue of dystrophin protein
synthesis in transduced muscles and to a concomitant
measurable improvement in functional parameters (that
is, specific force and force drop) compared with those in
unedited controls [41]. In addition, intraperitoneal co-
injection of rAAV-9 particles into dystrophic mice led to
frequencies of Dmd exon 23 excision in cardiac and
skeletal muscle tissues ranging from 3 to 18 %, as deter-
mined by real-time PCR, depending on the muscle
groups analyzed [41]. Importantly, Dmd-editing rAAV-9
particles were also administered intramuscularly or sys-
temically to Pax7-ZsGreen Dmdmdx mice whose satellite
cells are marked by green fluorescence. Subsequently,
after isolating, expanding, and inducing myogenic differ-
entiation of the Pax7-ZsGreen-positive cells, the authors
reported in-frame Dmd exon 23 deletions in myotubes
derived from these cells [41]. The population of Pax7-
positive satellite cells harbors the resident mononuclear
stem cell population of skeletal muscle and is typically
lodged between the sarcolemma of muscle fibers and the
basal lamina [53]. The “stemness” qualities of self-
renewal and lifelong differentiation capacity make these
tissue-specific stem cells ideal substrates for regenerative
medicine approaches for treating muscular dystrophies
as, in contrast to their committed progenitor offspring,
these cells support robust long-term tissue homeostasis
and repair [54, 55]. Recent experiments in transgenic
Dmdmdx mice showed that, in addition to its other func-
tions, dystrophin has a transient but critical regulatory
role in activated Pax7-positive satellite cells, which fur-
ther supports the therapeutic relevance of this cell popu-
lation. In particular, the 427-kilodalton dystrophin
isoform is expressed at very high levels in these cells,
where it governs asymmetric cell division, a process that
is indispensable for maintaining the stem cell pool and
for generating committed Myf5-positive myoblast pro-
genitors for muscle repair [56]. Among other processes,
this mechanism presumably involves interactions be-
tween the spectrin-like repeats R8 and R9 of dystrophin
and Mark2, a protein that regulates cell polarity [56, 57].
If conserved in humans, this cell-autonomous mechan-
ism would be evidence that DMD is also a stem cell dis-
ease, which would strengthen the view that satellite cells
should be preferential targets for DMD therapies. Inter-
estingly, the very high amounts of dystrophin seen in ac-
tivated Pax7-positive satellite cells are followed by very
low and intermediate levels of the protein in myoblasts
and differentiated muscle cells, respectively [56]. Such
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amounts strengthen the rationale for repairing the genetic
defects by direct endogenous DMD editing, as this strategy
is expected to restore proper regulation of dystrophin
synthesis.
Taken together, these findings demonstrate that rAAV
delivery of RGN complexes can result in the structural
improvement of treated striated tissues and also lead to
the partial rescue of specific muscle functions in dys-
trophic mice. Although dystrophin synthesis was
detected at 6 months after a single injection in one ex-
periment [40], no long-term detailed assessments of
these approaches were done. Regardless, the available
data do support the potential of these vectors as in vivo
DMD-repairing agents, thus warranting further research.
Future developments should include assuring the transi-
ent presence of programmable nucleases in post-mitotic
tissues, preclinical testing in large outbred animal
models [43], and identifying or engineering rAAV cap-
sids that have preferential tropism for human striated
muscle cells, including satellite cells, while bypassing the
host’s humoral immunity against prevalent AAV sero-
types [58].
The administration of rAAVs to some human individ-
uals resulted in clinical endpoints that had not been pre-
dicted on the basis of the available preclinical data.
These findings are simultaneously sobering and illumin-
ating. An example is provided by the elimination of
transduced hepatocytes in patients with hemophilia B,
which was due to the development of a dose-dependent
T-cell response to capsid epitopes from an rAAV-2
encoding the human factor IX [59]. This type of dose-
dependent cellular immune response has also been doc-
umented in human skeletal muscle cells transduced with
rAAVs [60], although it is of note that the emergence of
T-cell responses directed against rAAV capsid epitopes
does not always equate with the elimination of trans-
duced muscle cells [61]. In addition, short-term immune
suppression might help to dampen cellular immune
responses in muscular dystrophy patients subjected to
high-doses of rAAV particles [62]. It is worth mention-
ing, however, that the altered immune cell composition
and inflammatory environment that characterize
dystrophic muscle tissue might introduce potential
confounding factors associated with in vivo rAAV
delivery. Knowledge about these issues and preclinical
data obtained from canine models of DMD [63–65] are
guiding the design of new clinical trials based on the
administration of rAAVs to patients with DMD [66].
Further insights are also being gathered from the appli-
cation of rAAVs to patients suffering from other muscu-
lar disorders such as limb-girdle muscular dystrophy
caused by α-sarcoglycan deficiency [67]. In particular,
there is mounting evidence for the importance ofrestricting transgene expression to muscle cells by using
tissue-specific promoters [67]. In the future, muscle-
restricted transgene expression might be further im-
proved by combining transcriptional with transductional
targeting through rAAVs with capsids with a strict trop-
ism for human muscle tissue. The recently discovered
pan-AAV receptor AAVR [68] is likely to have an im-
portant role in this research; for instance, by shedding
light on rAAV transduction profiles in different cell
types, including immune-related cells. Therefore, al-
though rAAVs have a substantially milder immunogenic
profile than that of AdVs, they also need to be adapted
for translational in vivo gene-editing purposes, which, as
for AdVs, will be rooted in an increasing knowledge
about vector-host interactions and biodistribution at the
organismal level. Finally, in the context of future clinical
protocols for in vivo DMD editing, the synthesis of
programmable nucleases should be restricted not only
spatially but also temporally to limit immunological
issues as well as off-target DNA cleaving activities.
Ex vivo
Ex vivo DMD editing strategies to generate genetically
corrected human cells with myoregenerative capacity for
autologous transplantation can also be envisaged (Table 1).
These approaches offer a controlled genome-modification
environment, bypass vector-neutralizing antibodies, and
minimize direct contact between the patient and immuno-
genic components, such as those from vector particles,
gene-editing tools, and allogenic donor cells (Table 1).
Importantly, provided that clinically applicable delivery ve-
hicles of gene-editing tools become available, ex vivo
DMD editing can naturally build upon the numerous
investigations that are being conducted on the isolation,
characterization, and testing of human myogenic cells iso-
lated from different tissues for treating muscular dystro-
phies [69–73]. These cellular substrates include satellite
cells [53, 54] and their committed myoblast progeny [74],
induced pluripotent stem cells [75], mesenchymal stromal
cells [76, 77], vasculature-associated mesoangioblasts/peri-
cytes [78], and blood-derived CD133+ cells [79]. Of note,
the latter two cell types have been shown to be
amenable to systemic administration in animal models
and, to some extent, can transdifferentiate and
colonize their satellite cell niche [80–82]. In addition,
mesoangioblasts/pericytes and CD133+ cells have en-
tered early stage clinical testing in the context of allo-
genic cell therapies for DMD [83, 84]. These clinical
investigations complement earlier and ongoing testing of
allogenic myoblast transplantations that are based on
intramuscular injections [71–73, 85, 86].
Despite these encouraging developments, the hurdles
towards the clinical application of ex vivo DMD cell
therapies remain numerous and complex. Preeminent
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numbers of undifferentiated cells in vitro, as well as
robust cell engraftment, migration, and differentiation of
the transplanted graphs in vivo. Ideally, the transplanted
cells should also be capable of homing to damaged tissue
after systemic administration and should dedifferentiate
or transdifferentiate (when belonging to muscle and
non-muscle lineages, respectively) into satellite cells
(Table 1). Therefore, although certain therapeutic-cell
candidates are well positioned to fulfil some of these
criteria, none of them fulfils all of the criteria yet [69,
72]. For example, CD133+ blood-derived cells and
mesoangioblasts/pericytes have been shown to be com-
patible with systemic administration procedures in pre-
clinical models of muscular dystrophies [78, 79] but
their contribution to effective myoregeneration requires
further investigation. In contrast, the features of human
satellite cells make them natural, highly potent, muscle-
repairing entities. Besides being available in diverse hu-
man muscle groups, satellite cells have the capacity to
readily engraft as functional stem cells and robustly con-
tribute to de novo muscle repair in xenotransplantation
experiments [72]. However, harvested satellite cells are
not amenable to systemic administration or current
ex vivo culture conditions, as they readily differentiate
into myoblasts with a more reduced regenerative cap-
acity [87]. Importantly, the latter hurdle might not be in-
surmountable, as ongoing research indicates that
extrinsic factors such as the composition and elasticity
of culture vessels can be modulated to mimic the rigidity
of the native satellite cell niche (that is, 12 instead of
~106 kilopascals) and, in doing so, enable the in vitro
survival and self-renewal of bona fide satellite cells [88].
The development of such biomimetic tissue-engineering
technologies directed to the in vitro expansion of human
satellite cells is in demand.
In addition to that of skeletal muscle, cardiac muscle
impairment is a key component of DMD that also needs
to be tackled in future therapies. Despite intense
research on the isolation and characterization of stem
and progenitor cells for the repair of damaged heart
tissue (for example, after ischemia), so far there is no
evidence for a significant functional improvement of the
myocardium through the cell-autonomous differenti-
ation of the transplanted cells into mature, electrically
coupled cardiomyocytes [89, 90].
Other equally important areas for further research in
the field of DMD-targeted regenerative medicine are: (1)
deepening our knowledge about the origins and biology
of the various cell therapy candidates and their interac-
tion(s) with their respective niches; (2) gathering all
possible information on the behavior and fate of
transplanted cells from ongoing and future cell therapy
trials; (3) moving forward with gene replacementapproaches involving stable transduction of recombinant
constructs; and (4) testing different gene-editing re-
agents and strategies for developing autologous cell
transplantation approaches. Regarding the latter research
avenue, it will be crucial to efficiently introduce different
gene-editing tools into human muscle progenitor cells
and non-muscle cells with myogenic capacity. AdVs out-
perform rAAVs in ex vivo settings owing to their higher
functional vector particle titers, larger packaging cap-
acity (up to 37 kb), and faster kinetics of transgene ex-
pression [34, 52]. Our laboratory has recently reported
that tropism-modified AdVs are particularly efficient and
versatile vehicles for introducing RGNs and TALENs
into CAR-negative myoblasts from patients with DMD
[42]. The strict episomal nature of the transduced AdV
genomes enabled transient high-level expression of
programmable nucleases that corrected native DMD al-
leles and yielded permanent and regulated dystrophin
synthesis. In this work, we exploited targeted NHEJ-
mediated correction of DMD-causing intragenic dele-
tions by reading-frame resetting, DNA-borne exon skip-
ping, and in-frame excision of single or multiple exons
[42]. The rescue of dystrophin synthesis could be readily
detected in unselected populations of target cells [42].
Bypassing the need for cell selection expedients is
expected to simplify and help translate ex vivo DMD
editing protocols to the clinic. Moreover, AdV-based de-
livery systems will aid with assessing and comparing
different DMD editing reagents and strategies in panels
of human myogenic cells harboring the various DMD
mutations, which are not represented in the currently
available animal models. In addition, the well-defined
in vitro conditions permit the straightforward monitor-
ing of intended as well as unwarranted or potentially
deleterious interactions between the gene-editing re-
agents and the human genome (Table 1). Prominent
examples of such quality controls will include the
genome-wide tracking of adverse DNA-modifying events
directly in patient cells, chiefly those caused by off-target
activities of programmable nucleases.
Conclusions and future directions
The application of genome-editing principles for DMD
repair purposes is expanding the range of genetic therap-
ies for tackling DMD. In this context, the coopting of viral
vector systems as carriers of programmable nucleases is
set to have an important role in the path to DNA-targeted
DMD therapies and, along the way, in defining the best
strategies and optimizing the corresponding reagents. In
view of the complexity of the DMD phenotype and the ex-
tent of the affected tissues, it is sensible to consider that
future DMD therapies will profit from integrating comple-
mentary approaches. For example, the simultaneous treat-
ment of skeletal and cardiac tissues from patients with
Maggio et al. Genome Medicine  (2016) 8:59 Page 8 of 10DMD might be approached by combining ex vivo and
in vivo gene-editing strategies, respectively. Such schemes
can potentially address the skeletal and heart components
of DMD while circumventing the current lack of cell en-
tities capable of differentiating into functional cardiomyo-
cytes. Regardless of the particular therapy or combination
of therapies ultimately selected, there is widespread agree-
ment that they should preferably be applied as early as
possible so that most striated musculature is still in place
and the degeneration process can be halted or, ideally, re-
versed in the treated muscle groups. Finally, the insights
gained from these DMD-directed research efforts will
probably also be useful for devising advanced genetic ther-
apies for addressing other neuromuscular disorders for
which, at present, there are no therapeutic options
available.
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